The biological characteristics and pharmacodynamics of a mycophenolate mofetil nanosuspension ophthalmic delivery system in rabbits

Journal of Pharmaceutical Sciences

Volumn 100, Issue 4, 2011, Pages 1350-1361

  Wu, Xiang Gen ^a   Xin, Meng ^a   Yang, Li Na ^a   Shi, Wei Yun ^a  

^a SHANDONG EYE INSTITUTE   (China)

Author keywords

Absorption; Chitosan; Mucoadhesion; Mucosal drug delivery; Mycophenolate mofetil; Mycophenolic acid; Nanosuspension; Pharmacodynamics; Pharmacokinetics

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; CHITOSAN; EYE DROPS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; NANOMATERIAL;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; CORNEAL ALLOGRAFT; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG STABILITY; EXPERIMENTAL RABBIT; FEMALE; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; LACRIMAL FLUID; MALE; MUCOADHESION; NONHUMAN; PENETRATING KERATOPLASTY; PHARMACODYNAMICS; SURVIVAL TIME; ADHESION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CORNEA; DRUG EFFECTS; METABOLISM; PROCEDURES; RABBIT; SURGERY;

ADHESIVENESS; ANIMALS; CHITOSAN; CORNEA; CORNEAL TRANSPLANTATION; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; NANOSTRUCTURES; OPHTHALMIC SOLUTIONS; RABBITS;

EID: 79951883263     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22356     Document Type: Article

References (39)

1. Bachmann BO, Bock F, Wiegand SJ, Maruyama K, Dana MR, Kruse FE, Luetjen-Drecoll E, Cursiefen C. 2008. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126:71-77.
2. Shi W, Gao H, Xie L, Wang S. 2006. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 47:3339-3344.
3. Zhang X, Shen L, Jin Y, Saban DR, Chauhan SK, Dana R. 2009. Depletion of passenger leukocytes from corneal grafts: An effective means of promoting transplant survival?. Invest Ophthalmol Vis Sci 50:3137-3144.
4. Nieto E, Escudero E, Navarro E, Yanez-Mo M, Martin A, Perez de Lema G, Sanchez-Madrid F, Mampaso F. 2002. Effects of mycophenolate mofetil in mercury-induced autoimmune nephritis. J Am Soc Nephrol l13:937-945.
5. Zandman-Goddard G, Shoenfeld Y. 2005. Mycophenolate mofetil in animal models of autoimmune disease. Lupus 14 (suppl 1):s12- s16.
6. Birnbaum F, Bohringer D, Sokolovska Y, Sundmacher R, Reinhard T. 2005. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty:A retrospective study. Transpl 79:964-968.
7. Reinhard T, Kontopoulos T, Wernet P, Enczmann J, Sundmacher R. 2004. Long-term results of homologous penetrating limbokeratoplasty in total limbal stem cell insufficiency after chemical/thermal burns. Ophthalmologe 101:682-687.
8. Reinhard T, Reis A, Bohringer D, Malinowski M, Voiculescu A, Heering P, Godehardt E, Sunmacher R. 2001. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 239:367-372.
9. Reinhard T, Reis A, Kutkuhn B, Voiculescu A, Sundmacher R. 1999. Mycophenolate mofetil after penetrating high risk keratoplasty. A pilot study. Klin Monbl Augenheilkd 215:201-202.
10. Reisr A, Reinhard T, Voiculescu A, Mayer K, Sundmacher R. 2001. Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease. Klin Monbl Augenheilkd 218:183-186.
11. Zierhut M, Stubiger N, Siepmann K, Deuter CM. 2005. MMF and eye disease. Lupus 14 (suppl 1):s50-s54.
12. Reinhard T, Mayweg S, Sokolovska Y, Seitz B, Mittelviefhaus H, Engelmann K, Voiculescu A, Godehardt E, Sundmacher R. 2005. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: Preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int 18:703-708.
13. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. 2003. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110:1061-1065.
14. Bertelmann E, Pleyer U. 2004. Immunomodulatory therapy in ophthalmology- is there a place for topical application?. Ophthalmologica 218:359-367.
15. Patravale VB, Date AA, Kulkarni RM. 2004. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol l56:827-840.
16. Rabinow BE. 2004.Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785-796.
17. Rao GC, Kumar MS, Mathivanan N, Rao ME. 2004. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 59:5-9.
18. Gaudana R, Jwala J, Boddu SH, Mitra AK. 2009. Recent perspectives in ocular drug delivery. Pharm Res 26:1197-1216.
19. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. 2007. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340:126-133.
20. Sahoo SK, Dilnawaz F, Krishnakumar S. 2008. Nanotechnology in ocular drug delivery. Drug Discov Today 13:144-151.
21. de Campos AM, Diebold Y, Carvalho EL, Sanchez A, Alonso MJ. 2004. Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharm Res 21:803-810.
22. Qi H, Chen W, Huang C, Li L, Chen C, Li W, Wu C. 2007. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 337:178-187.
23. Aggarwal D, Kaur IP. 2005. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 290:155-159.
24. Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Rao YM. 2008. Polymers for mucoadhesive drug delivery system: A current status. Drug Dev Ind Pharm 34:1246-1266.
25. Ludwig A. 2005. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 57:1595-1639.
26. Knapp S, Bertelmann E, Hartmann C, Keipert S, Pleyer U. 2003. Intraocular availability of topically applied mycophenolate mofetil in rabbits. J Ocul Pharmacol Ther 19:181-192.
27. Alexopoulou E, Georgopoulos A, Kagkadis KA, Demetzos C. 2006. Preparation and characterization of lyophilized liposomes with incorporated quercetin. J Liposome Res 16:17-25.
28. Choy YB, Park JH, McCarey BE, Edelhauser HF, Prausnitz MR. 2008.Mucoadhesive microdiscs engineered for ophthalmic drug delivery: Effect of particle geometry and formulation on preocular residence time. Invest Ophthalmol Vis Sci 49:4808-4815.
29. Agnihotri SM, Vavia PR. 2009. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 5:90-95.
30. Mackie IA, Seal DV. 1976. Quantitative tear lysozyme assay in units of activity per microlitre. Br J Ophthalmol 60:70-74.
31. Ghelardi E, Tavanti A, Celandroni F, Lupetti A, Blandizzi C, Boldrini E, Campa M, Senesi S. 2000. Effect of a novel mucoadhesive polysaccharide obtained from tamarind seeds on the intraocular penetration of gentamicin and ofloxacin in rabbits. J Antimicrob Chemother 46:831-834.
32. Lim SJ, Kim CK. 2002. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 243:135-146.
33. Muller RH, Jacobs C. 2002. Buparvaquone mucoadhesive nanosuspension: Preparation, optimization, and long-term stability. Int J Pharm 237:151-161.
34. Kayser O, Lemke A, Hernandez-Trejo N. 2005. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol l6:3-5.
35. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. 2004. Cationic vectors in ocular drug delivery. J Drug Target 12:623-633.
36. Enriquez de Salamanca A, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S, Vila A, Alonso MJ. 2006. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism, and in vivo tolerance. Invest Ophthalmol Vis Sci 47:1416-1425.
37. Guan XP, Quan DP, Liao KR, Tao Wang, Peng Xiang, Mai KC. 2008. Preparation and characterization of cationic chitosan-modified poly(D, L-lactide-co-glycolide) copolymer nanospheres as DNA carriers. J Biomater App l22:353-371.
38. Jacobs C, Kayser O, Muller RH. 2001. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm 214:3-7.
39. Sonvico F, Cagnani A, Rossi A, Motta S, Di Bari MT, Cavatorta F, Alonso MJ, Deriu A, Colombo P. 2006. Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. Int J Pharm 324:67-73.